Engineered immune cells take on tough leukemia in early trial
NCT ID NCT07538713
First seen Apr 21, 2026 · Last updated May 16, 2026 · Updated 4 times
Summary
This early-stage study tests a new type of CAR-T cell therapy (FO33 CAR-T) for people with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target the CD33 protein found on most AML cells. The main goals are to check safety and see if the treatment can reduce or eliminate leukemia. About 18 participants will take part in this single-center trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CAR T CELL THERAPY are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.